Dr Nazia Riaz
Assistant Professor, Department of Surgery; PhD Student
Dr Nazia Riaz is an assistant professor and senior breast consultant in the Department of Surgery at the Aga Khan University Hospital, Karachi Campus. She is presently completing her PhD under the supervision of Professor El-Nasir M. A. Lalani.
Her clinical experience spans over ten years, where she has been engaged in developing comprehensive care plans and conducting surgeries through a multidisciplinary approach for both early and advanced breast cancers.
Dr Riaz is also a recipient of the Aga Khan University- Faculty of Health Sciences PhD Scholarship, where her PhD project is focused on understanding the functional role of androgen receptor and its association with cancer stem cell markers in Pakistani patients diagnosed with invasive breast cancer.
During her clinical practice, Dr Riaz observed a rising prevalence and incidence of Triple Negative Breast Cancer, an aggressive sub-type diagnosed amongst younger Pakistani female population. Therefore, to better understand the disease biology,
Dr Riaz's research is focused on investigating the role of androgen receptor in Triple-Negative Breast Cancer.
Further, Dr Riaz has developed, characterized and studied a unique metaplastic carcinoma of breast cell line derived from a Pakistani patient. She has presented her work at different international conferences.
Riaz, N, Idress, R, Habib, S, Hussain, AR, Lalani, E-N. Role of mesenchymal stem cells in acquisition of metaplasia in AKU-BC42 breast metaplastic carcinoma cell line. Poster session presented at: American Association of Cancer Research; 2017 Apr 1-5; Washington, DC.
Riaz, N, Idress, R, Habib, S, Hussain, AR, Lalani, E-N. Expression of androgen receptor and CD24 correlates with improved 5-year survival in Pakistani patients with invasive breast cancer. Poster session presented at: American Association of Cancer Research; 2017 Apr 1-5; Washington DC.
Riaz, N, Idress, R, Habib, S, Lalani, E-N. Lack of Androgen Receptor expression correlates with high expression of ALDH1 and poor over-all and 5-year disease-free survival in patients with invasive breast cancer. Poster session presented at: Recent Advances in Breast Cancer, American Association of Cancer Research Conference; 2015; 2015 Oct 17-20; Bellevue, Washington DC.
Riaz, N, Idress, R, Habib, S, Lalani, E-N. CD44-/ALDH1-/CD24+ phenotype is associated with improved overall and 5-year disease-free survival in a cohort of invasive breast cancer patients. Poster session presented at: 16th Milan Breast Cancer Conference; 2015 Jun 26-27; Milan.